Don’t Worry about the Drug Industry’s Profits When Considering a Waiver on COVID-19 Intellectual Property Rights
Share
>> Read article published by The BMJ
In an article published by The BMJ, PERI’s Lawrence King and colleagues argue that policy makers should prioritize public health over private monopolies in the debate around global access to COVID-19 vaccines and treatments.